Headache Inducing Effect of Cromakalim in Migraine Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03228355|
Recruitment Status : Recruiting
First Posted : July 24, 2017
Last Update Posted : February 14, 2018
|Condition or disease||Intervention/treatment||Phase|
|Headache, Migraine||Drug: Levcromakalim Drug: Saline||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effects of Levcromakalim on Cerebral Hemodynamic in Migraine Patients|
|Actual Study Start Date :||May 1, 2017|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2018|
|Active Comparator: Levcromakalim||
To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
|Placebo Comparator: Saline||
To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
- Cerebral hemodynamic [ Time Frame: Before (-10 min) and after infusion (+2 hours) of levcromakalim compared with before and after infusion of saline ]Change on Media cerebri arterie.
- Headache [ Time Frame: Before (-10 min) and after infusion (+12 hours) of levcromakalim compared with before and after infusion of saline ]Occurrence of headache.
- Migraine attack [ Time Frame: Before (-10 min) and after infusion (+12 hours) of levcromakalim compared with before and after infusion of saline ]Occurrence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03228355
|Contact: Mohammad A Al-Karagholi, MD||00 45 31 19 16 firstname.lastname@example.org|
|Danish headache center||Recruiting|
|Copenhagen, Glostrup, Denmark, 2600|
|Contact: Mohammad A Al-Karagholi, MD 00 45 31 19 16 47 email@example.com|
|Study Director:||Messoud Ashina, Professor||DHC|